The firm said it would use any net proceeds for R&D, working capital, and to potentially acquire other technologies or businesses.
Natera has focused on tapping into the average risk market for its suite of noninvasive prenatal assays, which it said is paying off.
The company's revenues were driven by sales of its Panorama NIPT and Horizon carrier screening tests.
The company said it planned to launch version 3 of Panorama this year during a conference call discussing its second quarter 2016 performance.
Test volume growth for its Panorama NIPT and Horizon carrier screening tests drove its revenues gains year over year.
Unilabs has licensed the rights to develop, validate, and run Natera's Panorama NIPT technology out of its own laboratories.
The firm did not disclose how it intended to use the $8 million, but said that it would provide temporary working capital.
Under the terms of the agreement, Natera will develop in vitro diagnostic products for oncology and pay Illumina milestone payments and royalties.
Natera said that a greater proportion of NIPTs for average-risk pregnancies are being reimbursed, while reimbursement for microdeletion testing is declining.
The company's first quarter revenues jumped due to an increase in NIPT and carrier screening testing volumes.